Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1 – News-Medical.Net

A cancer-specific L-type amino acid transporter 1 (LAT1) is highly expressed in cancer tissues. Inhibiting the function of LAT1 has been known to have anti-tumor effects, but there has been limited progress in the development of radionuclide therapy agents targeting LAT1. Now, a multidisciplinary research team at Osaka University has established a targeted alpha-therapy with a novel drug targeting LAT1.
The researchers first produced the alpha-ray emitter 211Astatine, no easy task given that Astatine…

Click here to view the original article.